Lithium Ion

Lithium Ion

SCHEMBL19743877

CCc1cnc(N)c(C(=O)[O-])n1.[Li+]

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 7/20 0.37
PRKCI P41743 1/20 0.37
MAPKAPK2 P49137 4/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36
GABRE P78334 1/20 0.36
GABRA6 Q16445 1/20 0.36
GABRG1 Q8N1C3 1/20 0.36
GABRG3 Q99928 1/20 0.36
GABRQ Q9UN88 1/20 0.36
PRKDC P78527 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19743909 0.83 NPSR1 (0.44) ATRPRKCIMAPKAPK2GABRA1GABRG2
SCHEMBL30852147 0.83 NPSR1 (0.44) ATRPRKCIMAPKAPK2GABRA1GABRG2
SCHEMBL3868054 0.83 GABRP (0.41) ATRPRKCIMAPKAPK2GABRPGABRD
Lithium Ion SCHEMBL19743870 0.77 GRM5 (0.50) ATRPRKCIMAPKAPK2GABRPGABRD
Lithium Ion SCHEMBL19743961 0.75 ATR (0.51) ATRPRKDCGRM5
Lithium Ion SCHEMBL19743866 0.74 ATR (0.33) ATRPRKDCGRM5
SCHEMBL3979134 0.72 GABRP (0.41) PRKCIMAPKAPK2GABRPGABRDGABRA1
SCHEMBL30852257 0.72 NPSR1 (0.42) ATRPRKCIMAPKAPK2GABRA1GABRG2
SCHEMBL6405355 0.72 MAPKAPK2 (0.41) MAPKAPK2DHFR
SCHEMBL13345759 0.70 MAPKAPK2 (0.47) MAPKAPK2GABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759785-B2 Compounds Enterprise Therapeutics Limited (GB) 2020-09-01 US disclosed
EP-3472154-B1 COMPOUNDS ENTERPRISE THERAPEUTICS LTD (GB) 2020-08-12 EP disclosed
US-20190233402-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2019-08-01 US disclosed
EP-3472154-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2019-04-24 EP disclosed
WO-2017221008-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233402-A1 COMPOUNDS CFTR, NHERF1, SCNN1A ATR 3410/4885PRKCI 2738/4885MAPKAPK2 4238/4885
US-10759785-B2 Compounds CFTR, NHERF1, SCNN1A ATR 3410/4885PRKCI 2738/4885MAPKAPK2 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.